Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 9/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609560 | 1.00 | MAPKAPK2 (0.50) | MAPKAPK2AURKAJAK2LCKMET | |
| SCHEMBL3616384 | 0.91 | MAPKAPK2 (0.50) | MAPKAPK2AURKAJAK2LCKMET | |
| SCHEMBL3616381 | 0.91 | MAPKAPK2 (0.50) | MAPKAPK2AURKAJAK2LCKMET | |
| SCHEMBL3611785 | 0.90 | MAPKAPK2 (0.48) | MAPKAPK2AURKAJAK2LCKMET | |
| SCHEMBL3611782 | 0.90 | MAPKAPK2 (0.48) | MAPKAPK2AURKAJAK2LCKMET | |
| SCHEMBL3609550 | 0.88 | MAPKAPK2 (0.47) | MAPKAPK2AURKAJAK2LCKMET | |
| SCHEMBL3609546 | 0.88 | MAPKAPK2 (0.47) | MAPKAPK2AURKAJAK2LCKMET | |
| SCHEMBL3610390 | 0.86 | MAPKAPK2 (0.46) | MAPKAPK2AURKAJAK2LCKMET | |
| SCHEMBL3622936 | 0.86 | MAPKAPK2 (0.46) | MAPKAPK2AURKAJAK2LCKMET | |
| SCHEMBL3619354 | 0.86 | MAPKAPK2 (0.46) | MAPKAPK2AURKAJAK2LCKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | claimed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | claimed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | claimed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | SLCO1B3, SLCO1B1, SLC10A6 | MAPKAPK2 4395/4885AURKA 1297/4885JAK2 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.